Spheryx, founded in New York, specializes in providing advanced services and instruments for the total holographic characterization of colloidal suspensions. Their core mission is to revolutionize particle characterization through innovative technology, enabling more accurate and comprehensive analysis of colloidal particles. Spheryx's primary product, Total Holographic Characterization (THC), offers significant advantages in detecting heterogeneous protein aggregates, making it particularly valuable in biopharmaceutical applications.
Notable affiliations include praise from The Journal of Pharmaceutical Sciences, highlighting THC's superiority over traditional methods like Flow Imaging (FI) and Resonant Mass Measurement (RMM). Spheryx's key achievements include significant advancements in the detection of sub-visible protein particles, impacting the quality control processes in the pharmaceutical industry. Overall, Spheryx has made a substantial impact by enhancing the precision and reliability of particle characterization, contributing to improved product safety and efficacy.
